I recently asked why aren’t there combination drugs for MRSA, and today I got my answer: Where’s the Combo?: Corante > In the Pipeline.
…
The answer is what you might suspect: the FDA would want clinical trials of the single-dose combination, just to make sure that things work the way that they’re supposed to. Any company developing the combo would have to recoup those costs, not to mention the costs of then beating the drum for the idea that the new combination is a better idea. But the antibiotics in question are generics, which means that there could be some real cost-containment issues over the use of a more expensive combination.
…
Now I know, and will sleep better tonight knowing the answer. Thanks, Dr. Lowe!
